Connect with us
  • Elysium


Your NR Headlines: Monday 12 February



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research developments 

Speeding up Parkinson’s diagnosis

Researchers have developed a new a molecular assay test technique that may lead to the development of tests that can diagnose Parkinson’s at an early stage, as well as potentially leading to the development of new treatments. The team from Brigham and Women’s Hospital and the Wyss Institute for Biologically Inspired Engineering at Harvard has developed a the test that detects alpha-synuclein fibrils in samples of brain tissue and cerebrospinal fluid from people with Parkinson’s disease.

Advancing early Alzheimer’s diagnosis

New findings published in findings Science Advances could lead to the early diagnosis and treatment of Alzheimer’s disease. Researchers at Vanderbilt University Medical Center have created a 3D map of brain activity that provides a detailed picture of how the brain changes with age, using white matter in brain imaging for the first time.

Drug opens new path for Parkinson’s treatment

In a new study, Rucaparib – a drug designed to treat several types of cancers that show alterations in DNA repair – and its metabolite, the M324 molecule, have been found to reduce the accumulation of the protein α-synuclein in neurons derived from patients with Parkinson’s. Researchers have suggested this activity highlights the therapeutic potential of this metabolite for the treatment of Parkinson’s.

Brain’s processing speed implicated in memory recall following brain injury

New findings have shown that the brain’s processing speed is slower in people with acquired brain injuries,  making it more difficult to create and recall memories. The team found processing speed to be a significant predictor of delayed verbal recall and overall memory.

Company updates 

Neurorehab system for walking shows positive safety results

MedRhythms has published two studies validating the efficacy, safety, and usability of InTandem™, a FDA-authorized, prescription-only neurorehabilitation system for home use to improve walking and ambulation in adults with chronic stroke. Results have confirmed the safe and effective use of InTandem by people with chronic stroke in the home environment.

Kyverna launches $319m IPO

Kyverna Therapeutics, Inc. has announced an initial public offering of  $319.0 million, with the offering is expected to close on or about February 12. The company is focused on developing cell therapies for patients suffering from autoimmune diseases, with its lead product candidate, KYV-101, currently advancing through clinical development in rheumatology and neurology.


AI tech shows positive outcomes for impact of neurology conditions

Viz.ai, which is focused on AI-powered disease detection and intelligent care coordination, has  announced new clinical data supporting advancements in neurovascular care. the company confirmed six studies which were presented at the International Stroke Conference (ISC) 2024 have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage.

AI can guide treatment decisions for stroke care

A new AI system has been designed to help guide treatment decisions for stroke patients led to improved stroke care quality and fewer recurrent strokes, heart attacks and vascular death among stroke survivors three months after a stroke. Findings presented at the American Stroke Association’s International Stroke Conference 2024 showed that ischemic stroke survivors who received care recommendations from the AI-based system had fewer recurrent strokes, heart attacks or vascular death within three months.